Viking Therapeutics, Inc.
Business
Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and type 2 diabetes in both subcutaneous and oral formulations. Additional pipeline programs include VK2809 (a thyroid hormone receptor beta agonist for NASH/MASH), VK0214 (a TRß agonist for X-linked adrenoleukodystrophy), a DACRA program for obesity, and VK5211 (a SARM for hip fracture recovery). The company operates globally through clinical development and contract manufacturing partnerships.
Summary from 10-K filed 2026-02-11
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 345 | 102 | 64 | 54 | 45 | |
| General and administrative | 48 | 49 | 37 | 16 | 11 | |
| Total operating expenses | 393 | 151 | 101 | 70 | 56 | |
| Loss from operations | −393 | −151 | −101 | −70 | −56 | |
| Amortization of financing costs | −56,000 | −94,000 | −88,000 | −59,000 | −18,000 | |
| Interest income, net | 34 | 41 | 15 | 2 | 703,000 | |
| Realized gain on investments, net | 55,000 | 112,000 | 0 | −42,000 | — | |
| Total other income, net | 34 | 41 | 15 | 1 | 692,000 | |
| Net loss | −360 | −110 | −86 | −69 | −55 | |
| Unrealized gain (loss) on securities | 1 | −173,000 | 742,000 | −295,000 | −495,000 | |
| Foreign currency translation gain (loss) | 47,000 | −226,000 | −29,000 | −258,000 | 0 | |
| Comprehensive loss | −358 | −110 | −85 | −69 | −55 | |
| Basic net loss per common share | −3.19 | −1.01 | −0.91 | −0.9 | −0.71 | |
| Weighted-average shares used to compute basic net loss per share | 113 | 109 | 94 | 77 | 77 | |
| Diluted net loss per common share | −3.19 | −1.01 | −0.91 | −0.9 | −0.71 | |
| Weighted-average shares used to compute diluted net loss per share | 113 | 109 | 94 | 77 | 77 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 166 | 27 | 56 | 37 | 26 | |
| Short-term investments available for sale | 540 | 876 | 307 | 119 | 176 | |
| Prepaid clinical trial and preclinical study costs | 8 | 3 | 3 | 8 | 8 | |
| Prepaid expenses and other current assets | 2 | 1 | 3 | 3 | 619,000 | |
| Total current assets | 716 | 907 | 367 | 167 | 211 | |
| Right-of-use assets | 85,000 | 1 | 1 | 1 | 25,000 | |
| Deferred financing costs | 0 | 56,000 | 106,000 | 38,000 | 76,000 | |
| Deposits | 46,000 | 46,000 | 33,000 | 33,000 | 33,000 | |
| Total assets | 716 | 908 | 368 | 169 | 211 | |
| Accounts payable | 53 | 10 | 8 | 9 | 1 | |
| Other accrued liabilities | 23 | 17 | 11 | 13 | 7 | |
| Lease liability, current | 137,000 | 489,000 | 324,000 | 304,000 | 29,000 | |
| Total current liabilities | 77 | 27 | 19 | 22 | 9 | |
| Lease liability, net of current portion | 0 | 630,000 | 936,000 | 1 | — | |
| Total long-term liabilities | 0 | 630,000 | 936,000 | 1 | — | |
| Total liabilities | 77 | 28 | 20 | 23 | 9 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
| Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024 | 0 | 0 | −7 | −7 | — | |
| Additional paid-in capital | 1,486 | 1,369 | 734 | 445 | 426 | |
| Accumulated deficit | −848 | −488 | −378 | −292 | −223 | |
| Accumulated other comprehensive loss | 378,000 | −788,000 | −389,000 | −1 | −549,000 | |
| Total stockholders equity | 639 | 880 | 348 | 145 | 202 | |
| Total liabilities and stockholders equity | 716 | 908 | 368 | 169 | 211 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −360 | −110 | −86 | −69 | −55 | |
| (Accretion) amortization of investment premiums | −9 | −17 | −8 | 1 | 4 | |
| Stock-based compensation | 41 | 30 | 17 | 9 | 6 | |
| Amortization of right-of-use assets | 431,000 | 346,000 | 292,000 | 291,000 | 296,000 | |
| Interest expense related to operating lease liability | 10,000 | 38,000 | 43,000 | 41,000 | 11,000 | |
| Prepaid expenses and other current assets | −5 | 446,000 | 6 | −3 | −711,000 | |
| Accrued interest, net of interest receivable on maturity of investments | 5 | 1 | 321,000 | 614,000 | 1 | |
| Accounts payable | 43 | 2 | −1 | 7 | −3 | |
| Accrued expenses | 6 | 6 | −2 | 6 | −506,000 | |
| Lease liability | −505,000 | −402,000 | −347,000 | −189,000 | −342,000 | |
| Net cash used in operating activities | −279 | −88 | −73 | −48 | −48 | |
| Purchases of investments | −418 | −1,113 | −478 | −121 | −168 | |
| Proceeds from sales and maturities of investments | 759 | 560 | 299 | 176 | 206 | |
| Net cash (used in) provided by investing activities | 341 | −553 | −179 | 55 | 38 | |
| Public offering, net of offering costs | 0 | 597 | 270 | −22,000 | −46,000 | |
| Value of shares withheld related to employee tax withholding | 0 | −42 | −7 | −2 | −707,000 | |
| Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan | 2 | 11 | 7 | 848,000 | 8 | |
| ATM offering, net of fees | 74 | 47 | 2 | 12 | — | |
| Net cash provided by financing activities | 76 | 612 | 271 | 4 | 7 | |
| Net (decrease) increase in cash and cash equivalents | 139 | −29 | 19 | 11 | −3 | |
| Effect of exchange rate changes on cash | −8,000 | −148,000 | −30,000 | −258,000 | — | |
| Unpaid deferred public offering and other financing costs | 50,000 | 50,000 | 50,000 | 31,000 | 50,000 | |
| Right-of-use asset obtained in exchange for lease obligation | 0 | 223,000 | 0 | 2 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Viking Therapeutics, Inc.'s CIK number?
Viking Therapeutics, Inc.'s SEC CIK number is 0001607678 (1607678). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Viking Therapeutics, Inc.'s SEC filings?
All of Viking Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Viking Therapeutics, Inc. last report earnings?
Viking Therapeutics, Inc. (VKTX) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-191487). This is Viking Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Viking Therapeutics, Inc.'s most recent earnings 8-K?
Viking Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0001193125-26-191487. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Viking Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →